Aegerion Pharmaceuticals (AEGR) Clinical Update on Lomitapide

Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Aegerion Pharmaceuticals Incorporated - AEGR - provided a clinical update on its lomitapide. Aegerion reported that the 78-week data from its pivotal Phase III clinical trial is consistent with data previously reported at the 26- and 56-week time points. According to the company, the data demonstrate that the reduction in LDL-C cholesterol from baseline was maintained at 78-weeks. Aegerion Pharmaceuticals’ Lomitapide is being evaluated for its ability to reduce low density lipoprotein (LDL-C) or bad cholesterol levels in patients with homozygous familial hypercholesterolemia. Aegerion Pharmaceuticals aspires to change the way rare, genetic lipid disorders are treated. Thanks for joining me and have a great day! For CRWE Newswire, Stocks to watch, I’m Shalika Jayasekera

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

1. By: karmastock
2. Categories News & Events
3. Views 11
4. Added :08-Jan-12
   Report This Video